I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...

WILMINGTON, DE — Prelude Therapeutics (Nasdaq: PRLD) presented encouraging interim results from its Phase 1 trial of PRT2527, an investigational CDK9 inhibitor, at the 66th American Society of ...

The company is also advancing SLS009, a small molecule CDK9 inhibitor with promising potential in treating acute myeloid leukemia. The press release includes forward-looking statements regarding ...

Upcoming data presentations, including those on the CDK9 inhibitor PRT2527, are eagerly anticipated and will be shared at the American Society of Hematology Annual Meeting.